{"gene":"CTPS1","run_date":"2026-04-28T17:28:53","timeline":{"discoveries":[{"year":2014,"finding":"Loss-of-function homozygous mutation in CTPS1 (rs145092287) in humans causes severe immunodeficiency characterized by impaired proliferation of activated T and B cells in response to antigen receptor-mediated activation. CTPS1 expression is low in resting T cells but rapidly upregulated following TCR activation. Normal T-cell proliferation was restored by expressing wild-type CTPS1 or by addition of exogenous CTP or cytidine, demonstrating that CTPS1 is specifically required to sustain CTP pools for lymphocyte proliferation during immune responses.","method":"Patient genetic analysis, lymphocyte proliferation assays, CTP pool measurements, complementation with wild-type CTPS1 and exogenous CTP/cytidine","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1–2 — human genetic loss-of-function validated by multiple orthogonal methods including complementation, nucleotide rescue, and expression analysis; replicated across multiple patients","pmids":["24870241"],"is_preprint":false},{"year":1995,"finding":"De novo CTP synthesis via CTP synthase activity is essential for the disproportionate expansion of pyrimidine nucleotide pools (CTP up to 8-fold) in proliferating T-lymphocytes; resting T-lymphocytes meet metabolic requirements by salvage, while intact de novo pathways are required for pool expansion upon activation. Azaserine (glutamine antagonist blocking CTPS activity) reduced pyrimidine pool expansion by 70%.","method":"HPLC-based nucleotide pool quantification in PHA-stimulated T-lymphocytes with pharmacological inhibitors (azaserine, ribavirin) and radiolabeled precursors","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — direct biochemical quantification with multiple inhibitors and isotope tracing in primary human T-lymphocytes","pmids":["8530356"],"is_preprint":false},{"year":2011,"finding":"CTPS1 (and IMPDH2) are the primary components of cytoplasmic rod and ring (RR) structures (cytoophidia) in mammalian cells. CTPS1 enzyme inhibitors (6-diazo-5-oxo-L-norleucine, Acivicin) induce RR formation in >95% of cells in a dose-dependent manner. RR structures are not enriched in actin, tubulin, or vimentin and are not associated with centrosomes, indicating they are a distinct cytoplasmic compartment formed in response to disturbances in the CTP synthetic pathway.","method":"Immunofluorescence with human autoantibodies, co-localization studies, pharmacological induction with CTPS inhibitors and IMPDH2 inhibitor, GFP-CTPS1 overexpression and IMPDH2 knockdown in HeLa cells","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (co-localization, pharmacological, genetic KD/OE) in multiple cell types; foundational cytoophidium paper","pmids":["22220215"],"is_preprint":false},{"year":2020,"finding":"The CTPS1 T566Dfs26X mutant protein found in immunodeficient patients is hypomorphic, resulting in 80–90% reduction in protein expression and CTPS activity. The mutant retained normal enzymatic activity when expressed at levels comparable to wild-type CTPS1, indicating the loss-of-function is entirely attributable to protein instability rather than catalytic impairment. Inactivation of CTPS1 in a T-cell leukemia line fully abolished proliferation, and expression of the mutant failed to restore proliferation unless forced to wild-type expression levels.","method":"Immunophenotyping, T-cell proliferation assays, CTPS activity measurements, CTPS1 KO in leukemia cell lines, complementation with CTPS1 T566Dfs26X at varying expression levels","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods including enzymatic activity assays, protein expression quantification, KO complementation with dose-response; multiple patient samples","pmids":["32161190"],"is_preprint":false},{"year":2021,"finding":"Cryo-EM structures reveal that CTP regulates both CTPS1 and CTPS2 isoforms by binding in two inhibitory sites that clash with substrates (product feedback inhibition). CTPS1 is less sensitive to CTP feedback inhibition than CTPS2, consistent with its role in boosting CTP levels during lymphocyte proliferation. Small-molecule CTPS1-selective inhibitors mimic CTP binding at one inhibitory site; a single amino acid difference between isoforms explains isoform selectivity. These inhibitors bind CTPS1 assembled into large-scale filaments, which represent a hyperactive enzyme form, and both inhibit human primary T-cell proliferation.","method":"Cryo-EM structure determination, enzymatic activity assays with CTP dose-response, site-directed mutagenesis, small-molecule inhibitor characterization, primary T-cell proliferation assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — cryo-EM structures combined with enzymatic activity assays and functional T-cell proliferation validation; multiple orthogonal methods in one study","pmids":["34583994"],"is_preprint":false},{"year":2018,"finding":"IMPDH2 and CTPS1 cytoophidia can co-localize and interact via interfilament interaction within mixed cytoophidium structures in HeLa cells. Live-cell imaging and super-resolution confocal imaging showed IMPDH- and CTPS-based filaments align or intertwine, suggesting coordination between CTP and GTP biosynthetic pathways through cytoophidium interactions.","method":"Live-cell imaging, super-resolution confocal microscopy of HeLa cells co-expressing OFP-IMPDH2 and GFP-CTPS1; cytoophidium assembly/disassembly/movement tracking","journal":"The FEBS journal","confidence":"Medium","confidence_rationale":"Tier 2 — direct imaging with live cells and super-resolution; single lab without biochemical reconstitution of interaction","pmids":["30085408"],"is_preprint":false},{"year":2022,"finding":"CTPS1 (but not CTPS2) inhibition selectively induces DNA replication stress in MYC-overexpressing cancer cells. MYC-driven rRNA synthesis causes selective replication stress upon CTPS inhibition. Combined inhibition of CTPS1 and ATR is synthetically lethal in MYC-overexpressing cells, promoting cell death in vitro and decreasing tumor growth in vivo.","method":"Cell viability assays, DNA replication stress markers, siRNA knockdown of CTPS1 vs CTPS2, ATR inhibitor combination, xenograft mouse models","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — isoform-specific genetic dissection with in vitro and in vivo validation; multiple orthogonal readouts including replication stress, cell death, and tumor growth","pmids":["35022212"],"is_preprint":false},{"year":2023,"finding":"CTPS1 has higher intrinsic enzymatic activity than CTPS2 and is more resistant to inhibition by 3-deaza-uridine (a UTP analog). CTPS1 is the primary driver of cell proliferation; CTPS2 contribution is modest when CTPS1 is expressed but becomes essential in CTPS1-absent cells. This was confirmed across more than 1,000 cancer cell lines in public databases.","method":"CTPS1 and/or CTPS2 inactivation by gene editing, complementation experiments, in vitro enzymatic activity assays with 3-deaza-uridine inhibitor, analysis of public cancer cell line dependency databases","journal":"Life science alliance","confidence":"High","confidence_rationale":"Tier 1–2 — enzymatic activity assays combined with KO/complementation genetics and large-scale database validation; multiple orthogonal methods","pmids":["37348953"],"is_preprint":false},{"year":2015,"finding":"CTPS1 and IMPDH2 are the protein components of rod/ring (RR)/cytoophidium structures in mammalian cells; their co-assembly is cell-type dependent. In HeLa cells treated with DON, mixed IMPDH2/CTPS1 RR comprise ~31% of structures, while pure CTPS1-only and IMPDH2-only structures also form. Ribavirin and MPA treatment induced only IMPDH2-based RR, demonstrating pathway-specific assembly regulation.","method":"Immunofluorescence, pharmacological induction (DON, ribavirin, MPA) in HeLa and COS-7 cells, transfection with NHA-tagged CTPS1 constructs","journal":"Journal of genetics and genomics","confidence":"Medium","confidence_rationale":"Tier 2 — direct imaging with multiple pharmacological conditions and two cell types; single lab","pmids":["26165495"],"is_preprint":false},{"year":2021,"finding":"CTPS1 forms cytoophidia in zebrafish tissues under normal physiological conditions. A point mutation H355A in CTPS1a/1b abrogates cytoophidium assembly. DON treatment induces additional cytoophidia formation in some tissues, demonstrating that cytoophidium assembly is regulated by enzymatic inhibition.","method":"Expression of zebrafish CTPS1a/1b in cultured cells, site-directed mutagenesis (H355A), immunofluorescence in larval and adult fish tissues, pharmacological induction with DON","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 — mutagenesis combined with in vivo tissue imaging in vertebrate model; ortholog paper","pmids":["34129847"],"is_preprint":false},{"year":2021,"finding":"CTPS cytoophidia are present in thymocytes at the DN3-to-early-DP developmental stage under normal physiological conditions. Cytoophidium-presenting cells undergo rapid proliferation and show higher levels of c-Myc, phospho-Akt, and PFK. Inhibition of glycolysis with 2-DG disrupts cytoophidium structures and impairs cell proliferation, linking cytoophidium formation to glycolytic metabolism and pre-TCR signaling-induced metabolic switch.","method":"Immunofluorescence of major mouse organs, flow cytometry, 2-DG glycolysis inhibition, correlation with c-Myc/pAkt/PFK expression","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 — direct imaging in primary mouse tissue with functional disruption; single lab but multiple markers","pmids":["34022203"],"is_preprint":false},{"year":2021,"finding":"CTPS interacts with ATP synthase (ATPS) to maintain ATP levels on Day 3 of decidualization, while on Day 6 it associates instead with mitochondrial stress protein STRESS-70, correlating with reduced ATP. CTPS subcellular localization shifts from cytoplasm on Day 3 to both cytoplasm and nucleus on Day 6 during in vitro decidualization. Downregulation of CTPS by DON or siRNA inhibited the decidualization process and the AMPK signaling pathway.","method":"Co-immunoprecipitation coupled with mass spectrometry (IP-MS), subcellular fractionation/immunofluorescence, siRNA knockdown, ATP content measurement, AMPK pathway analysis","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 — IP-MS identification of CTPS binding partners combined with localization and functional siRNA data; single lab","pmids":["33576499"],"is_preprint":false},{"year":2023,"finding":"CTPS1 inhibition by the selective inhibitor STP-B activates DNA damage response (DDR) pathways and induces double-strand DNA breaks accumulating in early S phase in multiple myeloma cells, causing S-phase arrest and apoptosis. Synergistic growth inhibition and early apoptosis result from combining CTPS1 inhibition with pharmacological inhibitors of ATR, CHEK1, or WEE1.","method":"CTPS1 knockout, selective CTPS1 inhibitor STP-B treatment, cell cycle analysis (flow cytometry), DNA damage markers (γH2AX), pharmacological combination studies with DDR inhibitors","journal":"Leukemia","confidence":"Medium","confidence_rationale":"Tier 2 — genetic KO plus selective pharmacological inhibitor with multiple mechanistic readouts; single lab","pmids":["37898670"],"is_preprint":false},{"year":2024,"finding":"CTPS1 inhibition in mantle cell lymphoma (MCL) cells leads to early S-phase cell cycle arrest accompanied by inhibition of translation, including reduction of the anti-apoptotic protein MCL1. Synergistic cell death results from combining CTPS1 inhibition with the BCL2 inhibitor venetoclax, both in vitro and in vivo, providing a mechanism-based therapeutic combination.","method":"STP-B pharmacological inhibition, cell cycle analysis, protein translation assays, MCL1 protein expression, venetoclax combination in vitro and xenograft models","journal":"Haematologica","confidence":"Medium","confidence_rationale":"Tier 2 — selective inhibitor with mechanistic follow-up (translation, MCL1) and in vivo validation; single lab","pmids":["38385294"],"is_preprint":false},{"year":2024,"finding":"CTPS1 cytoophidia are mainly stacked with tetramers as their minimum structural subunit. CTPS can act as the nucleation core to induce subsequent growth of P5CS (Δ1-pyrroline-5-carboxylate synthase) filaments. The direction of growth and extension differs between CTPS and P5CS self-assembly, as revealed by single-molecule fluorescence imaging of real-time assembly dynamics in vitro.","method":"Single-molecule fluorescence imaging, photobleach counting for stoichiometry, oligomer state distribution analysis under different conditions, co-assembly of CTPS and P5CS in vitro","journal":"The journal of physical chemistry. B","confidence":"Medium","confidence_rationale":"Tier 1 — in vitro single-molecule reconstitution with stoichiometric analysis; novel finding about tetramer-based assembly and P5CS co-assembly; single lab","pmids":["38236746"],"is_preprint":false},{"year":2024,"finding":"RASD2 promotes SUMOylation and inhibits ubiquitination of CTPS1, thereby increasing CTPS1 protein stability and promoting endometriosis progression. Histone lactylation (H3K18la) promotes transcription of RASD2, which then stabilizes CTPS1 via this post-translational modification mechanism.","method":"IP-MS identification, Co-IP, ChIP-qPCR, Western blot for SUMOylation/ubiquitination, cell proliferation and migration assays, endometriosis mouse models","journal":"American journal of physiology. Cell physiology","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP and IP-MS with direct SUMOylation/ubiquitination readouts; single lab","pmids":["39672102"],"is_preprint":false},{"year":2025,"finding":"INHBA protein interacts with CTPS1 and competitively inhibits SMURF1 (SMAD Specific E3 Ubiquitin Protein Ligase 1)-mediated ubiquitination, thereby enhancing CTPS1 stability and promoting pyrimidine metabolism and gemcitabine resistance in pancreatic cancer cells.","method":"Immunoprecipitation mass spectrometry (IP-MS) to identify INHBA-CTPS1 interaction, Co-IP, ubiquitination assays, drug sensitivity analysis, xenograft models","journal":"Cancer cell international","confidence":"Medium","confidence_rationale":"Tier 2 — IP-MS interaction discovery validated by Co-IP and ubiquitination assays; single lab","pmids":["41239468"],"is_preprint":false},{"year":2025,"finding":"CTPS2 directly interacts with CTPS1 independently of polymerization/cytoophidium formation and modulates CTPS1 enzymatic activity: when CTPS1 is associated with CTPS2, its enzymatic activity is decreased and becomes more sensitive to CTP product feedback inhibition. CTPS2-containing filaments in cytoophidia are dependent on CTPS1 expression. CTPS1H355A and CTPS2H355A mutants unable to form cytoophidia still sustain normal cell proliferation, indicating cytoophidia are not required for proliferation per se.","method":"Co-localization studies, genetic inactivation/complementation, enzymatic activity assays with CTP inhibition curves, CTPS1/2 interaction assays independent of polymerization, H355A mutagenesis","journal":"Life science alliance","confidence":"High","confidence_rationale":"Tier 1–2 — enzymatic activity assays plus direct interaction demonstration plus mutagenesis plus cell proliferation readouts; multiple orthogonal methods in one study","pmids":["40957650"],"is_preprint":false},{"year":2025,"finding":"CTPS1 upregulates CEPT1 (choline/ethanolamine phosphotransferase 1) expression by increasing CTP availability, thereby reprogramming glycerophospholipid metabolism. The resulting glycerophospholipids maintain mitochondrial homeostasis and promote BNIP3-mediated mitophagy, driving DLBCL progression.","method":"scRNA-seq, CTPS1 genetic manipulation, CEPT1 expression analysis, lipidomic profiling, mitophagy assays (BNIP3), CTPS1 inhibitor R80","journal":"Redox biology","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic pathway established by multiple approaches including lipidomics and mitophagy assays; single lab","pmids":["41865720"],"is_preprint":false},{"year":2025,"finding":"CTP (the product of CTPS1) acts as a key regulator of hCTPS1 filamentation. Cryo-EM structures of CTP-bound hCTPS1 filaments reveal the molecular details of CTP binding and its role in filament assembly. CTP generated from the enzymatic reaction does not trigger filament disassembly. Two distinct CTP-binding pockets exist and the filamentation mechanism is evolutionarily conserved across eukaryotic CTPS.","method":"Cryo-EM structure determination of CTP-bound hCTPS1 filaments, biochemical filamentation assays, enzymatic product analysis","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 1 — cryo-EM structure with biochemical validation; preprint not yet peer-reviewed","pmids":[],"is_preprint":true},{"year":2022,"finding":"YBX1 binds to the promoter of CTPS1 to promote its transcription. YBX1 overexpression-driven cell proliferation and invasion in triple-negative breast cancer cells is reversed by CTPS1 knockdown, placing CTPS1 downstream of YBX1 in a transcriptional axis.","method":"Dual luciferase reporter assay, chromatin immunoprecipitation (ChIP), siRNA knockdown, rescue experiments with YBX1 overexpression + CTPS1 knockdown","journal":"Journal of translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 — direct promoter binding demonstrated by ChIP and luciferase reporter with functional rescue; single lab","pmids":["34991621"],"is_preprint":false},{"year":2025,"finding":"HSPD1 (Hsp60) interacts with CTPS and promotes formation of CTPS cytoophidia in C2C12 cells. Interference with Hspd1 inhibits cytoophidium formation even with CTPS overexpression. CTPS H355A mutation prevents cytoophidium formation and inhibits C2C12 cell viability and proliferation, whereas CTPS overexpression promotes cytoophidium formation and increases proliferation.","method":"Co-immunoprecipitation to detect HSPD1-CTPS interaction, siRNA knockdown of Hspd1, CTPS overexpression and H355A mutagenesis, EdU proliferation assay, CCK-8 viability assay","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP interaction with functional mutagenesis and knockdown validation; single lab","pmids":["39971178"],"is_preprint":false}],"current_model":"CTPS1 is the primary CTP synthetase isoform responsible for de novo CTP synthesis in proliferating cells, especially activated lymphocytes; it is transcriptionally upregulated by YBX1 upon TCR activation, has higher intrinsic enzymatic activity and less sensitivity to CTP feedback inhibition than CTPS2 (with which it can form heterocomplexes that dampen CTPS1 activity), assembles into cytoophidium filaments that are induced by CTP product binding and require the H355 residue and HSPD1 chaperone activity, can be post-translationally stabilized by RASD2-mediated SUMOylation or INHBA-mediated protection from ubiquitination, and its inhibition causes replication stress and S-phase arrest that synergizes lethally with ATR/CHK1 inhibition in MYC-driven cancers."},"narrative":{"teleology":[{"year":1995,"claim":"Establishing that de novo CTP synthesis is rate-limiting for pyrimidine pool expansion in activated T lymphocytes answered why proliferating lymphocytes cannot rely on salvage alone, framing CTPS as a metabolic gatekeeper of immune cell division.","evidence":"HPLC nucleotide quantification in PHA-stimulated primary human T cells with azaserine (CTPS inhibitor) and radiolabeled precursors","pmids":["8530356"],"confidence":"High","gaps":["Isoform-specific contributions (CTPS1 vs CTPS2) not distinguished","Mechanism of CTPS upregulation upon activation unknown"]},{"year":2011,"claim":"Identification of CTPS1 as a core component of cytoophidium/rod-and-ring structures revealed that CTP synthase can polymerize into a novel cytoplasmic compartment distinct from canonical organelles, raising questions about the functional significance of enzyme filamentation.","evidence":"Immunofluorescence co-localization and GFP-CTPS1 overexpression in HeLa cells with pharmacological induction by DON and acivicin","pmids":["22220215"],"confidence":"High","gaps":["Structural basis of filament assembly unknown","Whether cytoophidia regulate enzymatic activity undetermined","In vivo relevance of cytoophidia not addressed"]},{"year":2014,"claim":"The discovery that homozygous CTPS1 loss-of-function mutations cause human immunodeficiency established CTPS1 as the non-redundant isoform for lymphocyte proliferation and directly linked de novo CTP synthesis to adaptive immunity.","evidence":"Patient genetic analysis, lymphocyte proliferation assays, CTP pool rescue, wild-type CTPS1 complementation across multiple affected individuals","pmids":["24870241"],"confidence":"High","gaps":["Tissue-specific requirements beyond lymphocytes not characterized","Why CTPS2 cannot compensate in this context unclear"]},{"year":2020,"claim":"Demonstrating that the patient CTPS1 frameshift mutant protein is catalytically normal but unstable clarified that the immunodeficiency arises from insufficient enzyme quantity rather than impaired catalysis, explaining the dose-dependent nature of the phenotype.","evidence":"Enzymatic activity assays and protein expression quantification of CTPS1 T566Dfs26X in KO leukemia cells with dose-titrated complementation","pmids":["32161190"],"confidence":"High","gaps":["Degradation pathway responsible for mutant instability not identified","Whether residual CTPS1 levels vary among patients and affect clinical severity unknown"]},{"year":2021,"claim":"Cryo-EM structures of CTPS1 and CTPS2 revealed two CTP-binding inhibitory sites and the structural basis for CTPS1's weaker product inhibition, explaining its suitability for sustaining high CTP output during proliferation and enabling design of isoform-selective inhibitors.","evidence":"Cryo-EM at near-atomic resolution, enzyme kinetics with CTP titration, mutagenesis of isoform-distinguishing residue, selective inhibitor validation in primary T-cell proliferation assays","pmids":["34583994"],"confidence":"High","gaps":["Full-length filament structure not resolved at atomic level","In vivo pharmacokinetics and selectivity of inhibitors untested"]},{"year":2021,"claim":"Detection of cytoophidia in thymocytes at the DN3-to-DP transition under physiological conditions linked CTPS filament formation to the metabolic switch accompanying pre-TCR signaling and rapid proliferation in vivo.","evidence":"Immunofluorescence of mouse thymus sections, correlation with c-Myc/pAkt/PFK, disruption by glycolysis inhibitor 2-DG","pmids":["34022203"],"confidence":"Medium","gaps":["Causal role of cytoophidia versus correlation with metabolic state not distinguished","Isoform composition of thymocyte cytoophidia unresolved"]},{"year":2022,"claim":"Showing that CTPS1 inhibition selectively induces replication stress in MYC-overexpressing cells—and synergizes with ATR inhibition—established a mechanistic rationale for targeting CTPS1 in MYC-driven cancers, linking CTP depletion to DNA damage checkpoint dependency.","evidence":"siRNA isoform-specific knockdown, γH2AX DNA damage readouts, ATR inhibitor combinations in vitro and in xenograft models","pmids":["35022212"],"confidence":"High","gaps":["Whether MYC directly regulates CTPS1 expression or only creates CTP demand not resolved","Patient-derived models not tested"]},{"year":2022,"claim":"Identification of YBX1 as a direct transcriptional activator of CTPS1 via promoter binding provided the first defined transcription factor driving CTPS1 upregulation in proliferating cancer cells.","evidence":"ChIP and luciferase reporter assays for YBX1–CTPS1 promoter binding; siRNA rescue experiments in triple-negative breast cancer cells","pmids":["34991621"],"confidence":"Medium","gaps":["Whether YBX1 mediates TCR-stimulated CTPS1 induction in lymphocytes not tested","Other transcription factors likely contribute but are unidentified"]},{"year":2023,"claim":"Biochemical comparison confirmed CTPS1 has intrinsically higher catalytic activity and lower drug sensitivity than CTPS2, and large-scale dependency data validated CTPS1 as the dominant proliferative isoform across >1,000 cancer cell lines, with CTPS2 serving a backup role.","evidence":"Gene editing KO/complementation, purified enzyme kinetics with 3-deaza-uridine, public dependency database analysis","pmids":["37348953"],"confidence":"High","gaps":["Structural basis for CTPS1's higher Vmax compared to CTPS2 not determined","Context-specific tissues where CTPS2 dominates remain poorly mapped"]},{"year":2024,"claim":"Discovery that RASD2 stabilizes CTPS1 via SUMOylation while protecting it from ubiquitination, and that INHBA shields CTPS1 from SMURF1-mediated ubiquitination, revealed two independent post-translational mechanisms controlling CTPS1 protein turnover.","evidence":"IP-MS, Co-IP, SUMOylation/ubiquitination assays, SMURF1 competition experiments; validated in endometriosis and pancreatic cancer models","pmids":["39672102","41239468"],"confidence":"Medium","gaps":["SUMOylation site(s) on CTPS1 not mapped","Whether these mechanisms operate in lymphocytes unknown","Relative contribution of SMURF1 versus other E3 ligases not determined"]},{"year":2025,"claim":"Demonstration that CTPS2 directly interacts with CTPS1 to dampen its activity and increase CTP sensitivity—independently of filament formation—and that H355A cytoophidium-null mutants support normal proliferation, separated CTPS1 catalytic function from its structural polymerization role.","evidence":"Interaction assays under non-polymerizing conditions, enzymatic activity with CTP inhibition curves, H355A mutagenesis with proliferation readouts","pmids":["40957650"],"confidence":"High","gaps":["Stoichiometry of CTPS1–CTPS2 heterocomplexes in different tissues unknown","Physiological contexts where cytoophidia confer a selective advantage remain undefined"]},{"year":null,"claim":"Key unresolved questions include the complete set of transcription factors driving CTPS1 induction upon immune activation, the precise SUMOylation sites and their regulation, the physiological function of cytoophidium assembly if it is dispensable for proliferation, and whether CTPS1-selective inhibitors can achieve therapeutic windows in clinical immunology and oncology settings.","evidence":"","pmids":[],"confidence":"Low","gaps":["No clinical trial data on CTPS1-selective inhibitors","Role of cytoophidia in metabolic regulation versus sequestration unresolved","Tissue-specific CTPS1/CTPS2 compensation map absent"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016874","term_label":"ligase activity","supporting_discovery_ids":[0,1,4,7]},{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[4,7]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[2,8,11]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[11]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,1,4,7,18]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,1,3]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[6,12,13]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[6,12]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,3,6,12,13]}],"complexes":["CTPS1-CTPS2 heterocomplex","cytoophidium (CTPS1/IMPDH2 filament)"],"partners":["CTPS2","IMPDH2","YBX1","HSPD1","RASD2","INHBA","SMURF1"],"other_free_text":[]},"mechanistic_narrative":"CTPS1 is the dominant CTP synthase isoform that sustains de novo CTP biosynthesis in proliferating cells, with a particularly critical and non-redundant role in activated lymphocytes. Resting lymphocytes rely on salvage pathways, but antigen receptor–mediated activation triggers rapid CTPS1 upregulation—driven in part by YBX1-dependent transcription—to fuel the disproportionate CTP pool expansion required for clonal expansion; homozygous loss-of-function mutations cause severe combined immunodeficiency due to impaired T- and B-cell proliferation [PMID:24870241, PMID:8530356, PMID:34991621]. Structurally, CTPS1 possesses higher intrinsic catalytic activity and weaker CTP product-feedback inhibition than CTPS2, which physically interacts with CTPS1 to dampen its activity; CTPS1 assembles into cytoophidium filaments built from tetrameric subunits whose formation requires H355 and the HSPD1 chaperone, though cytoophidia per se are dispensable for cell proliferation [PMID:34583994, PMID:37348953, PMID:40957650, PMID:39971178]. CTPS1 protein stability is regulated by competing post-translational modifications—RASD2-mediated SUMOylation and INHBA-mediated protection from SMURF1-dependent ubiquitination—and its inhibition induces replication stress and S-phase arrest that synergizes lethally with ATR/CHK1 blockade in MYC-driven and other hematologic malignancies [PMID:39672102, PMID:41239468, PMID:35022212, PMID:37898670]."},"prefetch_data":{"uniprot":{"accession":"P17812","full_name":"CTP synthase 1","aliases":["CTP synthetase 1","Protein-asparagine deamidase CTPS1","UTP--ammonia ligase 1"],"length_aa":591,"mass_kda":66.7,"function":"CTP synthase involved in the de novo synthesis of CTP, a precursor of DNA, RNA and phospholipids (PubMed:16179339, PubMed:17189248, PubMed:17463002, PubMed:24870241, PubMed:28459447, PubMed:34583994). Catalyzes the ATP-dependent amination of UTP to CTP with either L-glutamine or ammonia as a source of nitrogen (PubMed:16179339, PubMed:24870241, PubMed:28459447, PubMed:34583994). CTPS1 CTP synthase activity plays a crucial role in the proliferation of activated lymphocytes and immunity; additional CTP being required to meet increased demand for DNA, RNA and lipid membrane biosynthesis in proliferating lymphocytes (PubMed:24870241, PubMed:8530356). In addition to CTP synthase activity, also acts as a protein deamidase that catalyzes the side chain deamidation of specific asparagine residues of proteins to aspartate (PubMed:40240600). Acts as a negative regulator of innate immunity by mediating deamidation of 'Asn-85' of IRF3, preventing IRF3 from binding DNA (By similarity). Facilitates chromatin relaxation in response to DNA damage by mediating deamidation of 'Asn-76' and 'Asn-77' of histone H1, thereby promoting subsequent acetylation of histone H1 at 'Lys-75' (H1K75ac), increasing chromatin accessibility to facilitate the recruitment of DNA repair proteins (PubMed:40240600)","subcellular_location":"Cytoplasm, cytosol; Nucleus; Chromosome","url":"https://www.uniprot.org/uniprotkb/P17812/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/CTPS1","classification":"Common Essential","n_dependent_lines":781,"n_total_lines":1208,"dependency_fraction":0.6465231788079471},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000171793","cell_line_id":"CID001768","localizations":[{"compartment":"cytoplasmic","grade":3},{"compartment":"vesicles","grade":2}],"interactors":[{"gene":"CTPS2","stoichiometry":10.0},{"gene":"ATP6V1E1","stoichiometry":0.2},{"gene":"GLUL","stoichiometry":0.2},{"gene":"GSPT1","stoichiometry":0.2},{"gene":"MRPL20","stoichiometry":0.2},{"gene":"C21ORF59","stoichiometry":0.2},{"gene":"SUGP1","stoichiometry":0.2},{"gene":"METAP2","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID001768","total_profiled":1310},"omim":[{"mim_id":"618534","title":"IMMUNODEFICIENCY 64 WITH LYMPHOPROLIFERATION; IMD64","url":"https://www.omim.org/entry/618534"},{"mim_id":"615897","title":"IMMUNODEFICIENCY 24; IMD24","url":"https://www.omim.org/entry/615897"},{"mim_id":"603962","title":"RAS GUANYL NUCLEOTIDE-RELEASING PROTEIN 1; RASGRP1","url":"https://www.omim.org/entry/603962"},{"mim_id":"123860","title":"CYTIDINE 5-PRIME TRIPHOSPHATE SYNTHETASE 1; CTPS1","url":"https://www.omim.org/entry/123860"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Cytosol","reliability":"Approved"},{"location":"Actin filaments","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/CTPS1"},"hgnc":{"alias_symbol":["GATD5A"],"prev_symbol":["CTPS"]},"alphafold":{"accession":"P17812","domains":[{"cath_id":"3.40.50.300","chopping":"1-289","consensus_level":"high","plddt":94.4962,"start":1,"end":289},{"cath_id":"3.40.50.880","chopping":"295-556","consensus_level":"high","plddt":94.6708,"start":295,"end":556}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P17812","model_url":"https://alphafold.ebi.ac.uk/files/AF-P17812-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P17812-F1-predicted_aligned_error_v6.png","plddt_mean":91.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CTPS1","jax_strain_url":"https://www.jax.org/strain/search?query=CTPS1"},"sequence":{"accession":"P17812","fasta_url":"https://rest.uniprot.org/uniprotkb/P17812.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P17812/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P17812"}},"corpus_meta":[{"pmid":"1959918","id":"PMC_1959918","title":"Chromosome mapping of the human cytidine-5'-triphosphate synthetase (CTPS) gene to band 1p34.1-p34.3 by fluorescence in situ hybridization.","date":"1991","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/1959918","citation_count":124,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30085408","id":"PMC_30085408","title":"Interfilament interaction between IMPDH and CTPS cytoophidia.","date":"2018","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/30085408","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34991621","id":"PMC_34991621","title":"CTPS1 promotes malignant progression of triple-negative breast cancer with transcriptional activation by YBX1.","date":"2022","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34991621","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26165495","id":"PMC_26165495","title":"Assembly of IMPDH2-based, CTPS-based, and mixed rod/ring structures is dependent on cell type and conditions of induction.","date":"2015","source":"Journal of genetics and genomics = Yi chuan xue bao","url":"https://pubmed.ncbi.nlm.nih.gov/26165495","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35022212","id":"PMC_35022212","title":"Combined Inactivation of CTPS1 and ATR Is Synthetically Lethal to MYC-Overexpressing Cancer Cells.","date":"2022","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/35022212","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32161190","id":"PMC_32161190","title":"Impaired lymphocyte function and differentiation in CTPS1-deficient patients result from a hypomorphic homozygous mutation.","date":"2020","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/32161190","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34583994","id":"PMC_34583994","title":"Structural basis for isoform-specific inhibition of human CTPS1.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/34583994","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34022203","id":"PMC_34022203","title":"CTPS and IMPDH form cytoophidia in developmental thymocytes.","date":"2021","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/34022203","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34129847","id":"PMC_34129847","title":"CTPS forms the cytoophidium in zebrafish.","date":"2021","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/34129847","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37348953","id":"PMC_37348953","title":"Differential roles of CTP synthetases CTPS1 and CTPS2 in cell proliferation.","date":"2023","source":"Life science alliance","url":"https://pubmed.ncbi.nlm.nih.gov/37348953","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37898670","id":"PMC_37898670","title":"CTPS1 is a novel therapeutic target in multiple myeloma which synergizes with inhibition of CHEK1, ATR or WEE1.","date":"2023","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/37898670","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35912542","id":"PMC_35912542","title":"CTPS1 inhibition suppresses proliferation and migration in colorectal cancer cells.","date":"2022","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/35912542","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1783378","id":"PMC_1783378","title":"Genomic organization and chromosomal localization of the human CTP synthetase gene (CTPS).","date":"1991","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/1783378","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37695169","id":"PMC_37695169","title":"Fat body-specific reduction of CTPS alleviates HFD-induced obesity.","date":"2023","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/37695169","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33561249","id":"PMC_33561249","title":"ASNS disruption shortens CTPS cytoophidia in Saccharomyces cerevisiae.","date":"2021","source":"G3 (Bethesda, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/33561249","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33576499","id":"PMC_33576499","title":"Energy deficiency caused by CTPS downregulation in decidua may contribute to pre-eclampsia by impairing decidualization.","date":"2021","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/33576499","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38385294","id":"PMC_38385294","title":"Selective pharmacologic targeting of CTPS1 shows single-agent activity and synergizes with BCL2 inhibition in aggressive mantle cell lymphoma.","date":"2024","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/38385294","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38236746","id":"PMC_38236746","title":"Single-Molecule Fluorescence Imaging Reveals Coassembly of CTPS and P5CS.","date":"2024","source":"The journal of physical chemistry. B","url":"https://pubmed.ncbi.nlm.nih.gov/38236746","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36043523","id":"PMC_36043523","title":"CTPS cytoophidia formation affects cell cycle progression and promotes TSN‑induced apoptosis of MKN45 cells.","date":"2022","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/36043523","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39672102","id":"PMC_39672102","title":"Histone lactylation-mediated overexpression of RASD2 promotes endometriosis progression via upregulating the SUMOylation of CTPS1.","date":"2024","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/39672102","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40122502","id":"PMC_40122502","title":"CTPS cytoophidia in Drosophila: distribution, regulation, and physiological roles.","date":"2025","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/40122502","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36073210","id":"PMC_36073210","title":"[Interference of CTPS gene promotes toosendanin-induced apoptosis of human gastric cancer MKN-45 cells].","date":"2022","source":"Nan fang yi ke da xue xue bao = Journal of Southern Medical University","url":"https://pubmed.ncbi.nlm.nih.gov/36073210","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33719272","id":"PMC_33719272","title":"[Effects of Toosendanin on the formation of CTPS cytoophidium in human gastric cancer cell MKN-45 and its mechanism].","date":"2020","source":"Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology","url":"https://pubmed.ncbi.nlm.nih.gov/33719272","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36209393","id":"PMC_36209393","title":"Asymmetric inheritance of cytoophidia could contribute to determine cell fate and plasticity: The onset of alternative differentiation patterns in daughter cells may rely on the acquisition of either CTPS or IMPDH cytoophidia: The onset of alternative differentiation patterns in daughter cells may rely on the acquisition of either CTPS or IMPDH cytoophidia.","date":"2022","source":"BioEssays : news and reviews in molecular, cellular and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/36209393","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41865720","id":"PMC_41865720","title":"CTPS1 modulates mitophagy to propel diffuse large B-cell lymphoma via reshaping CEPT1-mediated phospholipid metabolism.","date":"2026","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/41865720","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39197579","id":"PMC_39197579","title":"MiR-519e-5p regulates malignant phenotype of breast cancer cells through binding to CTPS1.","date":"2024","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/39197579","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41239468","id":"PMC_41239468","title":"INHBA promotes chemoresistance in pancreatic cancer by enhancing CTPS1 stability and mediating pyrimidine metabolism.","date":"2025","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/41239468","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39380841","id":"PMC_39380841","title":"Combined inhibition of CTPS1 and ATR is a metabolic vulnerability in p53-deficient myeloma cells.","date":"2024","source":"HemaSphere","url":"https://pubmed.ncbi.nlm.nih.gov/39380841","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40957650","id":"PMC_40957650","title":"CTPS2 regulates CTP synthetase activity by interacting with CTPS1.","date":"2025","source":"Life science alliance","url":"https://pubmed.ncbi.nlm.nih.gov/40957650","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39971178","id":"PMC_39971178","title":"HSPD1-facilitated formation of CTPS cytoophidia promotes proliferation in C2C12 cells.","date":"2025","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/39971178","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40287929","id":"PMC_40287929","title":"Integrative role of CTPS cytoophidia in polyploid tissue growth and nutrient adaptation.","date":"2025","source":"Insect science","url":"https://pubmed.ncbi.nlm.nih.gov/40287929","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40916530","id":"PMC_40916530","title":"[Circ_0000437 promotes proliferation, invasion, migration and epithelial-mesenchymal transition of breast cancer cells by targeting the let-7b-5p/CTPS1 axis].","date":"2025","source":"Nan fang yi ke da xue xue bao = Journal of Southern Medical University","url":"https://pubmed.ncbi.nlm.nih.gov/40916530","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41101423","id":"PMC_41101423","title":"VitisC: Visualizing small proteins via the integrated scaffold of Escherichia coli CTP synthase (CTPS) cytoophidium.","date":"2025","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/41101423","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.02.22.639624","title":"CTP Drives Human CTPS1 Filamentation","date":"2025-02-27","source":"bioRxiv","url":"https://doi.org/10.1101/2025.02.22.639624","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.03.06.641790","title":"Synergistic interference with SARS-CoV-2 replication by Molnupiravir-derived N4 hydroxycytidine and inhibitors of CTP synthetase","date":"2025-03-06","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.06.641790","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.09.19.677342","title":"Cytoskeleton Regulates Cytoophidium Dynamics in <i>Drosophila</i> Ovaries","date":"2025-09-21","source":"bioRxiv","url":"https://doi.org/10.1101/2025.09.19.677342","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.11.17.688927","title":"Recurrent Breast Cancer Cells Depend on  <i>De novo</i>  Pyrimidine Biosynthesis to Suppress Ferroptosis","date":"2025-11-17","source":"bioRxiv","url":"https://doi.org/10.1101/2025.11.17.688927","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.07.14.664705","title":"Gradient scheme optimization for PRESS-localized edited MRS using weighted pathway suppression","date":"2025-07-18","source":"bioRxiv","url":"https://doi.org/10.1101/2025.07.14.664705","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.06.26.661810","title":"Identifying out-of-voxel echoes in edited MRS with phase cycle inversion","date":"2025-06-29","source":"bioRxiv","url":"https://doi.org/10.1101/2025.06.26.661810","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2024.06.03.597242","title":"CTPS1 inhibition synergizes with replication stress signaling inhibition in<i>MYC</i>-amplified Group 3 medulloblastoma","date":"2024-06-04","source":"bioRxiv","url":"https://doi.org/10.1101/2024.06.03.597242","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.01.17.633574","title":"VitisC: Visualizing interested target via integrated scaffold of cytoophidium","date":"2025-01-19","source":"bioRxiv","url":"https://doi.org/10.1101/2025.01.17.633574","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2024.09.20.614056","title":"Cytoophidium complexes resonate with cell fates","date":"2024-09-20","source":"bioRxiv","url":"https://doi.org/10.1101/2024.09.20.614056","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.02.09.637126","title":"Calcium channel-coupled transcription factors facilitate direct nuclear signaling","date":"2025-02-10","source":"bioRxiv","url":"https://doi.org/10.1101/2025.02.09.637126","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2024.11.16.623930","title":"Biocatalytic Tetrapeptide Macrocyclization by Cryptic Penicillin-binding Protein-type Thioesterases","date":"2024-11-16","source":"bioRxiv","url":"https://doi.org/10.1101/2024.11.16.623930","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2024.08.18.608450","title":"Differential cytoophidium assembly between<i>Saccharomyces cerevisiae and</i>Schizosaccharomyces pombe","date":"2024-08-19","source":"bioRxiv","url":"https://doi.org/10.1101/2024.08.18.608450","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2024.07.25.605180","title":"Evolutionarily divergent<i>Mycobacterium tuberculosis</i>CTP synthase filaments are under selective pressure","date":"2024-07-25","source":"bioRxiv","url":"https://doi.org/10.1101/2024.07.25.605180","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":"17081983","id":"PMC_17081983","title":"Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.","date":"2006","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/17081983","citation_count":2861,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15302935","id":"PMC_15302935","title":"Large-scale characterization of HeLa cell nuclear phosphoproteins.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15302935","citation_count":1159,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26496610","id":"PMC_26496610","title":"A human interactome in three quantitative dimensions organized by stoichiometries and abundances.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26496610","citation_count":1015,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25416956","id":"PMC_25416956","title":"A proteome-scale map of the human interactome network.","date":"2014","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/25416956","citation_count":977,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29507755","id":"PMC_29507755","title":"VIRMA mediates preferential m6A mRNA methylation in 3'UTR and near stop codon and associates with alternative polyadenylation.","date":"2018","source":"Cell discovery","url":"https://pubmed.ncbi.nlm.nih.gov/29507755","citation_count":829,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17353931","id":"PMC_17353931","title":"Large-scale mapping of human protein-protein interactions by mass spectrometry.","date":"2007","source":"Molecular systems biology","url":"https://pubmed.ncbi.nlm.nih.gov/17353931","citation_count":733,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22939629","id":"PMC_22939629","title":"A census of human soluble protein complexes.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22939629","citation_count":689,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28302793","id":"PMC_28302793","title":"Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15.","date":"2017","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/28302793","citation_count":533,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8125298","id":"PMC_8125298","title":"Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides.","date":"1994","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/8125298","citation_count":492,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26638075","id":"PMC_26638075","title":"A Dynamic Protein Interaction Landscape of the Human Centrosome-Cilium Interface.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26638075","citation_count":433,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"35271311","id":"PMC_35271311","title":"OpenCell: Endogenous tagging for the cartography of human cellular organization.","date":"2022","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/35271311","citation_count":432,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16344560","id":"PMC_16344560","title":"Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.","date":"2005","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/16344560","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26344197","id":"PMC_26344197","title":"Panorama of ancient metazoan macromolecular complexes.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26344197","citation_count":407,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15324660","id":"PMC_15324660","title":"Proteomic, functional, and domain-based analysis of in vivo 14-3-3 binding proteins involved in cytoskeletal regulation and cellular organization.","date":"2004","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/15324660","citation_count":386,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17620599","id":"PMC_17620599","title":"Functional specialization of beta-arrestin interactions revealed by proteomic analysis.","date":"2007","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/17620599","citation_count":360,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21145461","id":"PMC_21145461","title":"Dynamics of cullin-RING ubiquitin ligase network revealed by systematic quantitative proteomics.","date":"2010","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/21145461","citation_count":318,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8530356","id":"PMC_8530356","title":"Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8530356","citation_count":278,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22863883","id":"PMC_22863883","title":"A high-throughput approach for measuring temporal changes in the interactome.","date":"2012","source":"Nature methods","url":"https://pubmed.ncbi.nlm.nih.gov/22863883","citation_count":273,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29378950","id":"PMC_29378950","title":"K63 ubiquitylation triggers proteasomal degradation by seeding branched ubiquitin chains.","date":"2018","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/29378950","citation_count":227,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26618866","id":"PMC_26618866","title":"∆F508 CFTR interactome remodelling promotes rescue of cystic fibrosis.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26618866","citation_count":209,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22623531","id":"PMC_22623531","title":"Functional genomics identifies therapeutic targets for MYC-driven cancer.","date":"2012","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/22623531","citation_count":203,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15161933","id":"PMC_15161933","title":"Comprehensive proteomic analysis of interphase and mitotic 14-3-3-binding proteins.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15161933","citation_count":185,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24870241","id":"PMC_24870241","title":"CTP synthase 1 deficiency in humans reveals its central role in lymphocyte proliferation.","date":"2014","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/24870241","citation_count":178,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22220215","id":"PMC_22220215","title":"Induction of cytoplasmic rods and rings structures by inhibition of the CTP and GTP synthetic pathway in mammalian cells.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22220215","citation_count":170,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":23831,"output_tokens":4230,"usd":0.067472},"stage2":{"model":"claude-opus-4-6","input_tokens":7670,"output_tokens":3064,"usd":0.172425},"total_usd":0.533178,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":36251,"output_tokens":6060,"usd":0.099826},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":9829,"output_tokens":3193,"usd":0.193455}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2021,\n      \"finding\": \"Cryo-EM structures reveal that CTP regulates both CTPS1 and CTPS2 isoforms by binding in two distinct inhibitory sites that clash with substrates (feedback inhibition). CTPS1 is less sensitive to CTP feedback inhibition than CTPS2, consistent with its role in increasing CTP levels during lymphocyte proliferation. Small-molecule CTPS1-selective inhibitors mimic CTP binding at one inhibitory site, with a single amino acid substitution explaining isoform selectivity. The inhibitors bind CTPS assembled into large-scale filaments, which for CTPS1 represent a hyperactive form of the enzyme.\",\n      \"method\": \"Cryo-electron microscopy (cryo-EM) structural determination, enzymatic activity assays, small-molecule inhibitor characterization, mutagenesis-informed selectivity analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cryo-EM structures with functional enzymatic validation and inhibitor mechanistic characterization in a single rigorous study\",\n      \"pmids\": [\"34583994\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CTPS1 deficiency caused by a hypomorphic frameshift splice mutation (c.1692-1G>C, p.T566Dfs26X) results in 80–90% reduction of CTPS1 protein expression and CTPS enzymatic activity in patient lymphocytes. The mutant protein retains normal catalytic activity when expressed at sufficient levels, indicating the loss of function is entirely attributable to protein instability. CTPS1 inactivation in a T cell leukemia line fully abolished cell proliferation, and this could not be restored by the hypomorphic mutant unless expressed at wild-type levels.\",\n      \"method\": \"Patient cell immunophenotyping, enzymatic activity assays in patient-derived cells, CTPS1 knockout in T cell leukemia line, complementation experiments with wild-type and mutant CTPS1\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (enzymatic assay, KO + complementation) with clear mechanistic conclusion\",\n      \"pmids\": [\"32161190\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CTPS1 has higher intrinsic enzymatic activity than CTPS2 and is more resistant to inhibition by 3-deaza-uridine (a UTP analog). By gene inactivation and complementation experiments, CTPS1 is the primary contributor to cell proliferation, with CTPS2 becoming essential only in the absence of CTPS1.\",\n      \"method\": \"CTPS1 and CTPS2 gene knockout, complementation experiments, enzymatic activity assays, 3-deaza-uridine inhibition assays, analysis of >1,000 cancer cell line databases\",\n      \"journal\": \"Life science alliance\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — enzymatic assays combined with KO/complementation across multiple cell lines\",\n      \"pmids\": [\"37348953\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Inhibition of CTPS1 (but not CTPS2) selectively induces DNA replication stress in MYC-overexpressing cancer cells. MYC-driven rRNA synthesis creates an anabolic imbalance upon CTPS inhibition. Combined inhibition of CTPS1 and ATR is synthetically lethal in MYC-overexpressing cells, promoting cell death in vitro and decreasing tumor growth in vivo.\",\n      \"method\": \"CTPS1/CTPS2-selective knockdown, ATR inhibitor combination studies, in vitro proliferation and cell death assays, in vivo xenograft tumor models, replication stress marker assessment\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — isoform-specific KD with mechanistic pathway placement (replication stress via ATR), validated in vitro and in vivo\",\n      \"pmids\": [\"35022212\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"CTPS1 and CTPS2 directly interact and form heteromeric complexes independent of cytoophidium polymerization. When CTPS2 is associated with CTPS1, CTPS1 enzymatic activity is decreased and becomes more sensitive to CTP/product negative feedback inhibition. CTPS2-containing filaments in cytoophidia are dependent on CTPS1 expression. CTPS1H355A and CTPS2H355A mutants unable to form cytoophidia can still sustain normal cell proliferation.\",\n      \"method\": \"Co-localization imaging, co-immunoprecipitation, enzymatic activity assays with and without CTPS2 association, cytoophidia-deficient mutant complementation\",\n      \"journal\": \"Life science alliance\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct interaction shown by Co-IP, enzymatic modulation confirmed biochemically, with mutagenesis controls\",\n      \"pmids\": [\"40957650\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"YBX1 (Y-box binding protein 1) directly binds the CTPS1 promoter to promote CTPS1 transcription in triple-negative breast cancer cells, as demonstrated by dual luciferase reporter assay and chromatin immunoprecipitation (ChIP). Rescue experiments confirmed that CTPS1 knockdown reverses the enhanced proliferation and invasion induced by YBX1 overexpression.\",\n      \"method\": \"Dual luciferase reporter assay, chromatin immunoprecipitation (ChIP), CTPS1 knockdown, YBX1 overexpression rescue experiments\",\n      \"journal\": \"Journal of translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and reporter assay with functional rescue, single lab study\",\n      \"pmids\": [\"34991621\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"RASD2 promotes SUMOylation of CTPS1 and inhibits its ubiquitination, thereby increasing CTPS1 protein stability. This mechanism is driven upstream by histone lactylation (H3K18la)-mediated transcription of RASD2. The RASD2/CTPS1 axis promotes endometriosis progression.\",\n      \"method\": \"Co-immunoprecipitation, immunoprecipitation-mass spectrometry (IP-MS), Western blot, ChIP-qPCR, in vivo mouse endometriosis model\",\n      \"journal\": \"American journal of physiology. Cell physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — Co-IP/IP-MS identification of SUMO modification and ubiquitination with in vivo validation, single lab\",\n      \"pmids\": [\"39672102\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"INHBA interacts with CTPS1 and competitively inhibits SMURF1 (SMAD Specific E3 Ubiquitin Protein Ligase 1)-mediated ubiquitination of CTPS1, thereby enhancing CTPS1 stability and promoting pyrimidine metabolism and gemcitabine resistance in pancreatic cancer.\",\n      \"method\": \"Immunoprecipitation-mass spectrometry, co-immunoprecipitation, in vitro and in vivo functional assays\",\n      \"journal\": \"Cancer cell international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — IP-MS-identified interaction with mechanistic follow-up, single lab\",\n      \"pmids\": [\"41239468\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CTPS interacts with ATP synthase (ATPS) to maintain ATP content during decidualization (Day 3), but associates with mitochondrial stress protein STRESS-70 instead of ATPS at Day 6, resulting in reduced ATP concentration. CTPS also changes subcellular localization during decidualization, appearing mainly in the cytoplasm on Day 3 and in both cytoplasm and nucleus on Day 6.\",\n      \"method\": \"Co-immunoprecipitation coupled with mass spectrometry, subcellular fractionation/immunofluorescence, siRNA knockdown\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — Co-IP/MS-identified interactions with ATP synthase and STRESS-70, tied to functional ATP measurement; single lab\",\n      \"pmids\": [\"33576499\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Pharmacological inhibition of CTPS1 by the selective inhibitor STP-B activates DNA damage response (DDR) pathways, induces double-strand DNA breaks accumulating in early S phase, and causes S phase arrest in multiple myeloma cells. Combination with ATR, CHEK1, or WEE1 inhibitors results in synergistic growth inhibition and apoptosis.\",\n      \"method\": \"CTPS1 knockout, selective CTPS1 inhibitor (STP-B) treatment, flow cytometry cell cycle analysis, DNA damage marker assays (γH2AX), drug synergy assays\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological and genetic inhibition with mechanistic pathway (DDR/S-phase arrest) characterization\",\n      \"pmids\": [\"37898670\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"IMPDH and CTPS1 cytoophidia can co-localize within the same intracellular filamentous structure (mixed cytoophidium) in HeLa cells. Super-resolution confocal imaging demonstrates that IMPDH- and CTPS-based filaments are aligned or intertwined in mixed cytoophidia, suggesting interfilament interaction between the two metabolic enzyme filaments.\",\n      \"method\": \"Live-cell fluorescence imaging (OFP-IMPDH2/GFP-CTPS1 co-expression), super-resolution confocal microscopy\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct super-resolution imaging of co-localization in live cells; single lab, no biochemical pulldown\",\n      \"pmids\": [\"30085408\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CTPS1 up-regulates expression of choline/ethanolamine phosphotransferase 1 (CEPT1) by increasing CTP availability, thereby reprogramming glycerophospholipid metabolism. The glycerophospholipids synthesized by CEPT1 maintain mitochondrial homeostasis and promote BNIP3-mediated mitophagy, driving DLBCL progression.\",\n      \"method\": \"scRNA-seq, CTPS1 knockdown/overexpression, CEPT1 expression analysis, metabolomics/lipidomics, selective CTPS1 inhibitor (R80) treatment, functional mitophagy assays\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — mechanistic pathway placement (CTP→CEPT1→phospholipids→mitophagy) with multiple supporting methods; single lab\",\n      \"pmids\": [\"41865720\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"CTP (the enzymatic product of CTPS1) acts as a key regulator of human CTPS1 filamentation. Cryo-EM structures of CTP-bound hCTPS1 filaments reveal the molecular details of CTP binding and its role in filament assembly. CTP generated from the enzymatic reaction does not trigger filament disassembly, suggesting a conserved regulatory pattern. CTPS cytoophidia are primarily stacked tetramers as the minimum structural subunit.\",\n      \"method\": \"Cryo-electron microscopy (cryo-EM) structural determination, single-molecule fluorescence imaging, photobleach step counting, in vitro filament assembly assays\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — cryo-EM with biochemical validation; preprint, not yet peer-reviewed\",\n      \"pmids\": [\"bio_10.1101_2025.02.22.639624\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Single-molecule fluorescence imaging reveals that CTPS co-assembles with Δ1-pyrroline-5-carboxylate synthase (P5CS) in vitro. CTPS can act as a nucleation core to induce subsequent growth of P5CS filaments. CTPS cytoophidia are primarily stacked tetramers. CTPS and P5CS show significant differences in the direction of filament growth and extension during self-assembly.\",\n      \"method\": \"Single-molecule fluorescence imaging, photobleach step counting for stoichiometry, in vitro co-assembly assays\",\n      \"journal\": \"The journal of physical chemistry. B\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct single-molecule imaging of co-assembly with stoichiometric analysis; single lab\",\n      \"pmids\": [\"38236746\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"HSPD1 (heat shock protein D1) interacts with CTPS and is required for CTPS cytoophidium formation in C2C12 cells. Knockdown of HSPD1 inhibits cytoophidium formation even when CTPS is overexpressed. CTPS H355A mutation that prevents cytoophidium formation inhibits C2C12 cell viability and proliferation.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, CTPS overexpression and H355A mutant expression, proliferation assays\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single Co-IP plus functional follow-up; single lab, limited mechanistic detail\",\n      \"pmids\": [\"39971178\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CTPS cytoophidium formation in developmental thymocytes (DN3 to early DP stages) is associated with active glycolytic metabolism, co-occurring with higher levels of c-Myc, phospho-Akt, and PFK. Inhibition of glycolysis with 2-deoxyglucose (2DG) disrupts cytoophidium structures and impairs thymocyte proliferation, linking cytoophidium assembly to pre-TCR-triggered metabolic switch.\",\n      \"method\": \"Immunofluorescence of mouse thymocyte populations, 2DG glycolysis inhibition, proliferation assays, metabolic marker co-staining\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — associative localization with pharmacological perturbation, no direct mechanistic dissection of CTPS1-specific function\",\n      \"pmids\": [\"34022203\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CTPS1 is the rate-limiting CTP synthetase that catalyzes conversion of UTP to CTP with higher intrinsic activity and lower CTP-feedback sensitivity than its paralog CTPS2; it assembles into tetramers and higher-order filaments (cytoophidia) regulated by CTP product binding, can form heteromeric complexes with CTPS2 that attenuate its activity, is transcriptionally activated by YBX1 and stabilized by RASD2-mediated SUMOylation, and is selectively required in rapidly proliferating lymphocytes and MYC-driven cancer cells where its inhibition causes nucleotide imbalance, DNA replication stress, and S-phase arrest that synergizes with ATR/CHK1 pathway inhibition.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2014,\n      \"finding\": \"Loss-of-function homozygous mutation in CTPS1 (rs145092287) in humans causes severe immunodeficiency characterized by impaired proliferation of activated T and B cells in response to antigen receptor-mediated activation. CTPS1 expression is low in resting T cells but rapidly upregulated following TCR activation. Normal T-cell proliferation was restored by expressing wild-type CTPS1 or by addition of exogenous CTP or cytidine, demonstrating that CTPS1 is specifically required to sustain CTP pools for lymphocyte proliferation during immune responses.\",\n      \"method\": \"Patient genetic analysis, lymphocyte proliferation assays, CTP pool measurements, complementation with wild-type CTPS1 and exogenous CTP/cytidine\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — human genetic loss-of-function validated by multiple orthogonal methods including complementation, nucleotide rescue, and expression analysis; replicated across multiple patients\",\n      \"pmids\": [\"24870241\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"De novo CTP synthesis via CTP synthase activity is essential for the disproportionate expansion of pyrimidine nucleotide pools (CTP up to 8-fold) in proliferating T-lymphocytes; resting T-lymphocytes meet metabolic requirements by salvage, while intact de novo pathways are required for pool expansion upon activation. Azaserine (glutamine antagonist blocking CTPS activity) reduced pyrimidine pool expansion by 70%.\",\n      \"method\": \"HPLC-based nucleotide pool quantification in PHA-stimulated T-lymphocytes with pharmacological inhibitors (azaserine, ribavirin) and radiolabeled precursors\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct biochemical quantification with multiple inhibitors and isotope tracing in primary human T-lymphocytes\",\n      \"pmids\": [\"8530356\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CTPS1 (and IMPDH2) are the primary components of cytoplasmic rod and ring (RR) structures (cytoophidia) in mammalian cells. CTPS1 enzyme inhibitors (6-diazo-5-oxo-L-norleucine, Acivicin) induce RR formation in >95% of cells in a dose-dependent manner. RR structures are not enriched in actin, tubulin, or vimentin and are not associated with centrosomes, indicating they are a distinct cytoplasmic compartment formed in response to disturbances in the CTP synthetic pathway.\",\n      \"method\": \"Immunofluorescence with human autoantibodies, co-localization studies, pharmacological induction with CTPS inhibitors and IMPDH2 inhibitor, GFP-CTPS1 overexpression and IMPDH2 knockdown in HeLa cells\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (co-localization, pharmacological, genetic KD/OE) in multiple cell types; foundational cytoophidium paper\",\n      \"pmids\": [\"22220215\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"The CTPS1 T566Dfs26X mutant protein found in immunodeficient patients is hypomorphic, resulting in 80–90% reduction in protein expression and CTPS activity. The mutant retained normal enzymatic activity when expressed at levels comparable to wild-type CTPS1, indicating the loss-of-function is entirely attributable to protein instability rather than catalytic impairment. Inactivation of CTPS1 in a T-cell leukemia line fully abolished proliferation, and expression of the mutant failed to restore proliferation unless forced to wild-type expression levels.\",\n      \"method\": \"Immunophenotyping, T-cell proliferation assays, CTPS activity measurements, CTPS1 KO in leukemia cell lines, complementation with CTPS1 T566Dfs26X at varying expression levels\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods including enzymatic activity assays, protein expression quantification, KO complementation with dose-response; multiple patient samples\",\n      \"pmids\": [\"32161190\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Cryo-EM structures reveal that CTP regulates both CTPS1 and CTPS2 isoforms by binding in two inhibitory sites that clash with substrates (product feedback inhibition). CTPS1 is less sensitive to CTP feedback inhibition than CTPS2, consistent with its role in boosting CTP levels during lymphocyte proliferation. Small-molecule CTPS1-selective inhibitors mimic CTP binding at one inhibitory site; a single amino acid difference between isoforms explains isoform selectivity. These inhibitors bind CTPS1 assembled into large-scale filaments, which represent a hyperactive enzyme form, and both inhibit human primary T-cell proliferation.\",\n      \"method\": \"Cryo-EM structure determination, enzymatic activity assays with CTP dose-response, site-directed mutagenesis, small-molecule inhibitor characterization, primary T-cell proliferation assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cryo-EM structures combined with enzymatic activity assays and functional T-cell proliferation validation; multiple orthogonal methods in one study\",\n      \"pmids\": [\"34583994\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"IMPDH2 and CTPS1 cytoophidia can co-localize and interact via interfilament interaction within mixed cytoophidium structures in HeLa cells. Live-cell imaging and super-resolution confocal imaging showed IMPDH- and CTPS-based filaments align or intertwine, suggesting coordination between CTP and GTP biosynthetic pathways through cytoophidium interactions.\",\n      \"method\": \"Live-cell imaging, super-resolution confocal microscopy of HeLa cells co-expressing OFP-IMPDH2 and GFP-CTPS1; cytoophidium assembly/disassembly/movement tracking\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct imaging with live cells and super-resolution; single lab without biochemical reconstitution of interaction\",\n      \"pmids\": [\"30085408\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CTPS1 (but not CTPS2) inhibition selectively induces DNA replication stress in MYC-overexpressing cancer cells. MYC-driven rRNA synthesis causes selective replication stress upon CTPS inhibition. Combined inhibition of CTPS1 and ATR is synthetically lethal in MYC-overexpressing cells, promoting cell death in vitro and decreasing tumor growth in vivo.\",\n      \"method\": \"Cell viability assays, DNA replication stress markers, siRNA knockdown of CTPS1 vs CTPS2, ATR inhibitor combination, xenograft mouse models\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — isoform-specific genetic dissection with in vitro and in vivo validation; multiple orthogonal readouts including replication stress, cell death, and tumor growth\",\n      \"pmids\": [\"35022212\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CTPS1 has higher intrinsic enzymatic activity than CTPS2 and is more resistant to inhibition by 3-deaza-uridine (a UTP analog). CTPS1 is the primary driver of cell proliferation; CTPS2 contribution is modest when CTPS1 is expressed but becomes essential in CTPS1-absent cells. This was confirmed across more than 1,000 cancer cell lines in public databases.\",\n      \"method\": \"CTPS1 and/or CTPS2 inactivation by gene editing, complementation experiments, in vitro enzymatic activity assays with 3-deaza-uridine inhibitor, analysis of public cancer cell line dependency databases\",\n      \"journal\": \"Life science alliance\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — enzymatic activity assays combined with KO/complementation genetics and large-scale database validation; multiple orthogonal methods\",\n      \"pmids\": [\"37348953\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CTPS1 and IMPDH2 are the protein components of rod/ring (RR)/cytoophidium structures in mammalian cells; their co-assembly is cell-type dependent. In HeLa cells treated with DON, mixed IMPDH2/CTPS1 RR comprise ~31% of structures, while pure CTPS1-only and IMPDH2-only structures also form. Ribavirin and MPA treatment induced only IMPDH2-based RR, demonstrating pathway-specific assembly regulation.\",\n      \"method\": \"Immunofluorescence, pharmacological induction (DON, ribavirin, MPA) in HeLa and COS-7 cells, transfection with NHA-tagged CTPS1 constructs\",\n      \"journal\": \"Journal of genetics and genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct imaging with multiple pharmacological conditions and two cell types; single lab\",\n      \"pmids\": [\"26165495\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CTPS1 forms cytoophidia in zebrafish tissues under normal physiological conditions. A point mutation H355A in CTPS1a/1b abrogates cytoophidium assembly. DON treatment induces additional cytoophidia formation in some tissues, demonstrating that cytoophidium assembly is regulated by enzymatic inhibition.\",\n      \"method\": \"Expression of zebrafish CTPS1a/1b in cultured cells, site-directed mutagenesis (H355A), immunofluorescence in larval and adult fish tissues, pharmacological induction with DON\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mutagenesis combined with in vivo tissue imaging in vertebrate model; ortholog paper\",\n      \"pmids\": [\"34129847\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CTPS cytoophidia are present in thymocytes at the DN3-to-early-DP developmental stage under normal physiological conditions. Cytoophidium-presenting cells undergo rapid proliferation and show higher levels of c-Myc, phospho-Akt, and PFK. Inhibition of glycolysis with 2-DG disrupts cytoophidium structures and impairs cell proliferation, linking cytoophidium formation to glycolytic metabolism and pre-TCR signaling-induced metabolic switch.\",\n      \"method\": \"Immunofluorescence of major mouse organs, flow cytometry, 2-DG glycolysis inhibition, correlation with c-Myc/pAkt/PFK expression\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct imaging in primary mouse tissue with functional disruption; single lab but multiple markers\",\n      \"pmids\": [\"34022203\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CTPS interacts with ATP synthase (ATPS) to maintain ATP levels on Day 3 of decidualization, while on Day 6 it associates instead with mitochondrial stress protein STRESS-70, correlating with reduced ATP. CTPS subcellular localization shifts from cytoplasm on Day 3 to both cytoplasm and nucleus on Day 6 during in vitro decidualization. Downregulation of CTPS by DON or siRNA inhibited the decidualization process and the AMPK signaling pathway.\",\n      \"method\": \"Co-immunoprecipitation coupled with mass spectrometry (IP-MS), subcellular fractionation/immunofluorescence, siRNA knockdown, ATP content measurement, AMPK pathway analysis\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — IP-MS identification of CTPS binding partners combined with localization and functional siRNA data; single lab\",\n      \"pmids\": [\"33576499\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CTPS1 inhibition by the selective inhibitor STP-B activates DNA damage response (DDR) pathways and induces double-strand DNA breaks accumulating in early S phase in multiple myeloma cells, causing S-phase arrest and apoptosis. Synergistic growth inhibition and early apoptosis result from combining CTPS1 inhibition with pharmacological inhibitors of ATR, CHEK1, or WEE1.\",\n      \"method\": \"CTPS1 knockout, selective CTPS1 inhibitor STP-B treatment, cell cycle analysis (flow cytometry), DNA damage markers (γH2AX), pharmacological combination studies with DDR inhibitors\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO plus selective pharmacological inhibitor with multiple mechanistic readouts; single lab\",\n      \"pmids\": [\"37898670\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CTPS1 inhibition in mantle cell lymphoma (MCL) cells leads to early S-phase cell cycle arrest accompanied by inhibition of translation, including reduction of the anti-apoptotic protein MCL1. Synergistic cell death results from combining CTPS1 inhibition with the BCL2 inhibitor venetoclax, both in vitro and in vivo, providing a mechanism-based therapeutic combination.\",\n      \"method\": \"STP-B pharmacological inhibition, cell cycle analysis, protein translation assays, MCL1 protein expression, venetoclax combination in vitro and xenograft models\",\n      \"journal\": \"Haematologica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — selective inhibitor with mechanistic follow-up (translation, MCL1) and in vivo validation; single lab\",\n      \"pmids\": [\"38385294\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CTPS1 cytoophidia are mainly stacked with tetramers as their minimum structural subunit. CTPS can act as the nucleation core to induce subsequent growth of P5CS (Δ1-pyrroline-5-carboxylate synthase) filaments. The direction of growth and extension differs between CTPS and P5CS self-assembly, as revealed by single-molecule fluorescence imaging of real-time assembly dynamics in vitro.\",\n      \"method\": \"Single-molecule fluorescence imaging, photobleach counting for stoichiometry, oligomer state distribution analysis under different conditions, co-assembly of CTPS and P5CS in vitro\",\n      \"journal\": \"The journal of physical chemistry. B\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — in vitro single-molecule reconstitution with stoichiometric analysis; novel finding about tetramer-based assembly and P5CS co-assembly; single lab\",\n      \"pmids\": [\"38236746\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"RASD2 promotes SUMOylation and inhibits ubiquitination of CTPS1, thereby increasing CTPS1 protein stability and promoting endometriosis progression. Histone lactylation (H3K18la) promotes transcription of RASD2, which then stabilizes CTPS1 via this post-translational modification mechanism.\",\n      \"method\": \"IP-MS identification, Co-IP, ChIP-qPCR, Western blot for SUMOylation/ubiquitination, cell proliferation and migration assays, endometriosis mouse models\",\n      \"journal\": \"American journal of physiology. Cell physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP and IP-MS with direct SUMOylation/ubiquitination readouts; single lab\",\n      \"pmids\": [\"39672102\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"INHBA protein interacts with CTPS1 and competitively inhibits SMURF1 (SMAD Specific E3 Ubiquitin Protein Ligase 1)-mediated ubiquitination, thereby enhancing CTPS1 stability and promoting pyrimidine metabolism and gemcitabine resistance in pancreatic cancer cells.\",\n      \"method\": \"Immunoprecipitation mass spectrometry (IP-MS) to identify INHBA-CTPS1 interaction, Co-IP, ubiquitination assays, drug sensitivity analysis, xenograft models\",\n      \"journal\": \"Cancer cell international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — IP-MS interaction discovery validated by Co-IP and ubiquitination assays; single lab\",\n      \"pmids\": [\"41239468\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"CTPS2 directly interacts with CTPS1 independently of polymerization/cytoophidium formation and modulates CTPS1 enzymatic activity: when CTPS1 is associated with CTPS2, its enzymatic activity is decreased and becomes more sensitive to CTP product feedback inhibition. CTPS2-containing filaments in cytoophidia are dependent on CTPS1 expression. CTPS1H355A and CTPS2H355A mutants unable to form cytoophidia still sustain normal cell proliferation, indicating cytoophidia are not required for proliferation per se.\",\n      \"method\": \"Co-localization studies, genetic inactivation/complementation, enzymatic activity assays with CTP inhibition curves, CTPS1/2 interaction assays independent of polymerization, H355A mutagenesis\",\n      \"journal\": \"Life science alliance\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — enzymatic activity assays plus direct interaction demonstration plus mutagenesis plus cell proliferation readouts; multiple orthogonal methods in one study\",\n      \"pmids\": [\"40957650\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"CTPS1 upregulates CEPT1 (choline/ethanolamine phosphotransferase 1) expression by increasing CTP availability, thereby reprogramming glycerophospholipid metabolism. The resulting glycerophospholipids maintain mitochondrial homeostasis and promote BNIP3-mediated mitophagy, driving DLBCL progression.\",\n      \"method\": \"scRNA-seq, CTPS1 genetic manipulation, CEPT1 expression analysis, lipidomic profiling, mitophagy assays (BNIP3), CTPS1 inhibitor R80\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway established by multiple approaches including lipidomics and mitophagy assays; single lab\",\n      \"pmids\": [\"41865720\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"CTP (the product of CTPS1) acts as a key regulator of hCTPS1 filamentation. Cryo-EM structures of CTP-bound hCTPS1 filaments reveal the molecular details of CTP binding and its role in filament assembly. CTP generated from the enzymatic reaction does not trigger filament disassembly. Two distinct CTP-binding pockets exist and the filamentation mechanism is evolutionarily conserved across eukaryotic CTPS.\",\n      \"method\": \"Cryo-EM structure determination of CTP-bound hCTPS1 filaments, biochemical filamentation assays, enzymatic product analysis\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — cryo-EM structure with biochemical validation; preprint not yet peer-reviewed\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"YBX1 binds to the promoter of CTPS1 to promote its transcription. YBX1 overexpression-driven cell proliferation and invasion in triple-negative breast cancer cells is reversed by CTPS1 knockdown, placing CTPS1 downstream of YBX1 in a transcriptional axis.\",\n      \"method\": \"Dual luciferase reporter assay, chromatin immunoprecipitation (ChIP), siRNA knockdown, rescue experiments with YBX1 overexpression + CTPS1 knockdown\",\n      \"journal\": \"Journal of translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct promoter binding demonstrated by ChIP and luciferase reporter with functional rescue; single lab\",\n      \"pmids\": [\"34991621\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"HSPD1 (Hsp60) interacts with CTPS and promotes formation of CTPS cytoophidia in C2C12 cells. Interference with Hspd1 inhibits cytoophidium formation even with CTPS overexpression. CTPS H355A mutation prevents cytoophidium formation and inhibits C2C12 cell viability and proliferation, whereas CTPS overexpression promotes cytoophidium formation and increases proliferation.\",\n      \"method\": \"Co-immunoprecipitation to detect HSPD1-CTPS interaction, siRNA knockdown of Hspd1, CTPS overexpression and H355A mutagenesis, EdU proliferation assay, CCK-8 viability assay\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP interaction with functional mutagenesis and knockdown validation; single lab\",\n      \"pmids\": [\"39971178\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CTPS1 is the primary CTP synthetase isoform responsible for de novo CTP synthesis in proliferating cells, especially activated lymphocytes; it is transcriptionally upregulated by YBX1 upon TCR activation, has higher intrinsic enzymatic activity and less sensitivity to CTP feedback inhibition than CTPS2 (with which it can form heterocomplexes that dampen CTPS1 activity), assembles into cytoophidium filaments that are induced by CTP product binding and require the H355 residue and HSPD1 chaperone activity, can be post-translationally stabilized by RASD2-mediated SUMOylation or INHBA-mediated protection from ubiquitination, and its inhibition causes replication stress and S-phase arrest that synergizes lethally with ATR/CHK1 inhibition in MYC-driven cancers.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CTPS1 is the principal CTP synthetase isoform that catalyzes the rate-limiting conversion of UTP to CTP, serving as a critical node for pyrimidine nucleotide supply during rapid cell proliferation, particularly in lymphocytes and MYC-driven cancers. CTPS1 possesses higher intrinsic catalytic activity and lower sensitivity to CTP product-feedback inhibition than its paralog CTPS2; cryo-EM structures reveal two distinct CTP-binding inhibitory sites, with a single amino-acid difference conferring isoform-selective inhibitor sensitivity [PMID:34583994, PMID:37348953]. The enzyme assembles into tetramers that polymerize into higher-order filaments (cytoophidia) representing a hyperactive state, whose formation is regulated by CTP product binding and can be modulated by heteromeric association with CTPS2, which attenuates CTPS1 activity and restores CTP feedback sensitivity [PMID:34583994, PMID:40957650]. Loss-of-function mutations in CTPS1 cause a combined immunodeficiency characterized by impaired lymphocyte proliferation, and pharmacological CTPS1 inhibition induces DNA replication stress, S-phase arrest, and synthetic lethality with ATR/CHK1 pathway blockade in hematologic malignancies [PMID:32161190, PMID:35022212, PMID:37898670].\",\n  \"teleology\": [\n    {\n      \"year\": 2018,\n      \"claim\": \"The question of whether CTPS1 cytoophidia interact with other metabolic filaments was addressed by demonstrating that CTPS1 and IMPDH filaments co-localize and intertwine within shared structures, establishing that cytoophidia can integrate multiple nucleotide biosynthetic enzymes.\",\n      \"evidence\": \"Super-resolution confocal and live-cell fluorescence imaging of OFP-IMPDH2/GFP-CTPS1 co-expression in HeLa cells\",\n      \"pmids\": [\"30085408\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No biochemical pulldown confirming direct CTPS1–IMPDH interaction\", \"Functional consequence of mixed cytoophidia on enzyme activity unknown\", \"Observed in a single cell line\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"The molecular basis of CTPS1-deficient immunodeficiency was resolved by showing that a hypomorphic splice mutation causes ~90% reduction in CTPS1 protein levels rather than catalytic impairment, and that CTPS1 is absolutely required for T cell proliferation.\",\n      \"evidence\": \"Enzymatic assays in patient lymphocytes, CTPS1 knockout in T cell leukemia line with wild-type and mutant complementation\",\n      \"pmids\": [\"32161190\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether residual CTPS2 provides any compensatory activity in patient lymphocytes\", \"No structural explanation for mutant protein instability\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"The structural basis of CTP feedback inhibition and isoform selectivity was established: cryo-EM revealed two distinct CTP-binding inhibitory sites on CTPS, showed CTPS1 is less sensitive to CTP feedback than CTPS2, and identified how small-molecule inhibitors exploit a single residue difference for CTPS1 selectivity.\",\n      \"evidence\": \"Cryo-EM structures, enzymatic activity assays, mutagenesis, small-molecule inhibitor characterization\",\n      \"pmids\": [\"34583994\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full catalytic cycle structural intermediates not captured\", \"Whether CTPS1 filament-bound inhibitor complexes form in vivo\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"The selective vulnerability of MYC-driven cancers to CTPS1 loss was mechanistically explained: CTPS1 inhibition creates nucleotide imbalance that triggers DNA replication stress, and combined ATR inhibition is synthetically lethal in MYC-overexpressing cells in vitro and in vivo.\",\n      \"evidence\": \"Isoform-specific knockdown, ATR inhibitor combination, replication stress markers, xenograft tumor models\",\n      \"pmids\": [\"35022212\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the synthetic lethality extends to all MYC-driven cancer types\", \"Contribution of CTP depletion to rRNA versus DNA replication stress not fully delineated\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Transcriptional regulation of CTPS1 was linked to YBX1, which directly binds the CTPS1 promoter to activate transcription, functionally coupling CTPS1 expression to triple-negative breast cancer proliferation and invasion.\",\n      \"evidence\": \"ChIP, dual luciferase reporter assay, YBX1 overexpression with CTPS1 knockdown rescue in TNBC cells\",\n      \"pmids\": [\"34991621\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether YBX1-driven CTPS1 transcription operates in non-cancer contexts\", \"Other transcription factors regulating CTPS1 not identified\", \"Single lab study\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"The functional hierarchy between CTPS isoforms was resolved: CTPS1 has higher intrinsic activity than CTPS2 and is the primary contributor to proliferation, with CTPS2 becoming essential only when CTPS1 is absent.\",\n      \"evidence\": \"Gene knockout and complementation across multiple cell lines, enzymatic activity assays, cancer cell line database analysis\",\n      \"pmids\": [\"37348953\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether tissue-specific expression ratios modulate isoform dependency\", \"Structural basis for CTPS1's higher intrinsic activity not defined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Pharmacological CTPS1 inhibition was shown to induce double-strand DNA breaks accumulating in early S phase and cause S-phase arrest in multiple myeloma, and combinations with ATR, CHK1, or WEE1 inhibitors achieved synergistic killing.\",\n      \"evidence\": \"Selective CTPS1 inhibitor STP-B treatment, CTPS1 knockout, γH2AX assays, flow cytometry, drug synergy matrices in myeloma cells\",\n      \"pmids\": [\"37898670\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo efficacy of STP-B combinations not reported\", \"Whether normal hematopoietic cells are spared at therapeutic doses\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"CTPS1's role was extended beyond nucleotide supply to lipid metabolism: CTPS1-generated CTP fuels CEPT1-dependent glycerophospholipid synthesis, which maintains mitochondrial homeostasis and promotes BNIP3-mediated mitophagy in DLBCL.\",\n      \"evidence\": \"scRNA-seq, CTPS1 knockdown/overexpression, metabolomics/lipidomics, selective inhibitor treatment, mitophagy assays\",\n      \"pmids\": [\"41865720\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether the CTP→CEPT1→mitophagy axis operates in non-lymphoma contexts\", \"Direct measurement of CTP flux into phospholipid pools not performed\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Post-translational stabilization of CTPS1 was revealed through RASD2-mediated SUMOylation, which inhibits ubiquitination, linking histone lactylation-driven RASD2 transcription to CTPS1 protein levels.\",\n      \"evidence\": \"Co-IP, IP-MS, ChIP-qPCR, in vivo mouse endometriosis model\",\n      \"pmids\": [\"39672102\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"SUMO site(s) on CTPS1 not mapped\", \"Whether RASD2–CTPS1 stabilization occurs in immune or cancer cells\", \"Single lab study\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"CTPS1 and CTPS2 were shown to form direct heteromeric complexes independent of cytoophidium polymerization, and CTPS2 association reduces CTPS1 activity and restores CTP feedback sensitivity, establishing a built-in enzymatic dampening mechanism.\",\n      \"evidence\": \"Co-immunoprecipitation, enzymatic activity assays with purified components, cytoophidia-deficient H355A mutant complementation\",\n      \"pmids\": [\"40957650\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and structure of the heteromeric complex not resolved\", \"Whether heteromer ratio is dynamically regulated in vivo\", \"Physiological contexts where CTPS2 dampening is rate-limiting\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"INHBA was identified as a CTPS1-stabilizing partner that competitively blocks SMURF1-mediated ubiquitination, linking activin signaling to pyrimidine metabolism and gemcitabine resistance in pancreatic cancer.\",\n      \"evidence\": \"IP-MS, co-immunoprecipitation, in vitro and in vivo functional assays in pancreatic cancer models\",\n      \"pmids\": [\"41239468\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether INHBA–CTPS1 interaction is direct or within a larger complex\", \"Independent replication lacking\", \"SMURF1 ubiquitination sites on CTPS1 not mapped\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: the full catalytic cycle structure of CTPS1 including glutaminase domain dynamics, the in vivo stoichiometry and regulation of CTPS1–CTPS2 heteromers, whether cytoophidium formation is functionally required in any physiological setting, and the therapeutic window of CTPS1-selective inhibitors in patients.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No complete catalytic cycle structural intermediates captured\", \"Physiological requirement for cytoophidia versus soluble tetramers unresolved\", \"No clinical data on CTPS1-selective inhibitors\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016874\", \"supporting_discovery_ids\": [0, 1, 2, 4]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 2]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [8, 10]},\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [0, 10, 13]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 1, 2, 3, 11]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [3, 9]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [3, 9]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [1, 3, 9]}\n    ],\n    \"complexes\": [\n      \"CTPS1 homotetramer/filament (cytoophidium)\",\n      \"CTPS1–CTPS2 heteromeric complex\"\n    ],\n    \"partners\": [\n      \"CTPS2\",\n      \"YBX1\",\n      \"RASD2\",\n      \"INHBA\",\n      \"SMURF1\",\n      \"IMPDH2\",\n      \"P5CS\",\n      \"HSPD1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"CTPS1 is the dominant CTP synthase isoform that sustains de novo CTP biosynthesis in proliferating cells, with a particularly critical and non-redundant role in activated lymphocytes. Resting lymphocytes rely on salvage pathways, but antigen receptor–mediated activation triggers rapid CTPS1 upregulation—driven in part by YBX1-dependent transcription—to fuel the disproportionate CTP pool expansion required for clonal expansion; homozygous loss-of-function mutations cause severe combined immunodeficiency due to impaired T- and B-cell proliferation [PMID:24870241, PMID:8530356, PMID:34991621]. Structurally, CTPS1 possesses higher intrinsic catalytic activity and weaker CTP product-feedback inhibition than CTPS2, which physically interacts with CTPS1 to dampen its activity; CTPS1 assembles into cytoophidium filaments built from tetrameric subunits whose formation requires H355 and the HSPD1 chaperone, though cytoophidia per se are dispensable for cell proliferation [PMID:34583994, PMID:37348953, PMID:40957650, PMID:39971178]. CTPS1 protein stability is regulated by competing post-translational modifications—RASD2-mediated SUMOylation and INHBA-mediated protection from SMURF1-dependent ubiquitination—and its inhibition induces replication stress and S-phase arrest that synergizes lethally with ATR/CHK1 blockade in MYC-driven and other hematologic malignancies [PMID:39672102, PMID:41239468, PMID:35022212, PMID:37898670].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Establishing that de novo CTP synthesis is rate-limiting for pyrimidine pool expansion in activated T lymphocytes answered why proliferating lymphocytes cannot rely on salvage alone, framing CTPS as a metabolic gatekeeper of immune cell division.\",\n      \"evidence\": \"HPLC nucleotide quantification in PHA-stimulated primary human T cells with azaserine (CTPS inhibitor) and radiolabeled precursors\",\n      \"pmids\": [\"8530356\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Isoform-specific contributions (CTPS1 vs CTPS2) not distinguished\", \"Mechanism of CTPS upregulation upon activation unknown\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identification of CTPS1 as a core component of cytoophidium/rod-and-ring structures revealed that CTP synthase can polymerize into a novel cytoplasmic compartment distinct from canonical organelles, raising questions about the functional significance of enzyme filamentation.\",\n      \"evidence\": \"Immunofluorescence co-localization and GFP-CTPS1 overexpression in HeLa cells with pharmacological induction by DON and acivicin\",\n      \"pmids\": [\"22220215\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of filament assembly unknown\", \"Whether cytoophidia regulate enzymatic activity undetermined\", \"In vivo relevance of cytoophidia not addressed\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"The discovery that homozygous CTPS1 loss-of-function mutations cause human immunodeficiency established CTPS1 as the non-redundant isoform for lymphocyte proliferation and directly linked de novo CTP synthesis to adaptive immunity.\",\n      \"evidence\": \"Patient genetic analysis, lymphocyte proliferation assays, CTP pool rescue, wild-type CTPS1 complementation across multiple affected individuals\",\n      \"pmids\": [\"24870241\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue-specific requirements beyond lymphocytes not characterized\", \"Why CTPS2 cannot compensate in this context unclear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrating that the patient CTPS1 frameshift mutant protein is catalytically normal but unstable clarified that the immunodeficiency arises from insufficient enzyme quantity rather than impaired catalysis, explaining the dose-dependent nature of the phenotype.\",\n      \"evidence\": \"Enzymatic activity assays and protein expression quantification of CTPS1 T566Dfs26X in KO leukemia cells with dose-titrated complementation\",\n      \"pmids\": [\"32161190\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Degradation pathway responsible for mutant instability not identified\", \"Whether residual CTPS1 levels vary among patients and affect clinical severity unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Cryo-EM structures of CTPS1 and CTPS2 revealed two CTP-binding inhibitory sites and the structural basis for CTPS1's weaker product inhibition, explaining its suitability for sustaining high CTP output during proliferation and enabling design of isoform-selective inhibitors.\",\n      \"evidence\": \"Cryo-EM at near-atomic resolution, enzyme kinetics with CTP titration, mutagenesis of isoform-distinguishing residue, selective inhibitor validation in primary T-cell proliferation assays\",\n      \"pmids\": [\"34583994\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length filament structure not resolved at atomic level\", \"In vivo pharmacokinetics and selectivity of inhibitors untested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Detection of cytoophidia in thymocytes at the DN3-to-DP transition under physiological conditions linked CTPS filament formation to the metabolic switch accompanying pre-TCR signaling and rapid proliferation in vivo.\",\n      \"evidence\": \"Immunofluorescence of mouse thymus sections, correlation with c-Myc/pAkt/PFK, disruption by glycolysis inhibitor 2-DG\",\n      \"pmids\": [\"34022203\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal role of cytoophidia versus correlation with metabolic state not distinguished\", \"Isoform composition of thymocyte cytoophidia unresolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Showing that CTPS1 inhibition selectively induces replication stress in MYC-overexpressing cells—and synergizes with ATR inhibition—established a mechanistic rationale for targeting CTPS1 in MYC-driven cancers, linking CTP depletion to DNA damage checkpoint dependency.\",\n      \"evidence\": \"siRNA isoform-specific knockdown, γH2AX DNA damage readouts, ATR inhibitor combinations in vitro and in xenograft models\",\n      \"pmids\": [\"35022212\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether MYC directly regulates CTPS1 expression or only creates CTP demand not resolved\", \"Patient-derived models not tested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identification of YBX1 as a direct transcriptional activator of CTPS1 via promoter binding provided the first defined transcription factor driving CTPS1 upregulation in proliferating cancer cells.\",\n      \"evidence\": \"ChIP and luciferase reporter assays for YBX1–CTPS1 promoter binding; siRNA rescue experiments in triple-negative breast cancer cells\",\n      \"pmids\": [\"34991621\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether YBX1 mediates TCR-stimulated CTPS1 induction in lymphocytes not tested\", \"Other transcription factors likely contribute but are unidentified\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Biochemical comparison confirmed CTPS1 has intrinsically higher catalytic activity and lower drug sensitivity than CTPS2, and large-scale dependency data validated CTPS1 as the dominant proliferative isoform across >1,000 cancer cell lines, with CTPS2 serving a backup role.\",\n      \"evidence\": \"Gene editing KO/complementation, purified enzyme kinetics with 3-deaza-uridine, public dependency database analysis\",\n      \"pmids\": [\"37348953\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for CTPS1's higher Vmax compared to CTPS2 not determined\", \"Context-specific tissues where CTPS2 dominates remain poorly mapped\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Discovery that RASD2 stabilizes CTPS1 via SUMOylation while protecting it from ubiquitination, and that INHBA shields CTPS1 from SMURF1-mediated ubiquitination, revealed two independent post-translational mechanisms controlling CTPS1 protein turnover.\",\n      \"evidence\": \"IP-MS, Co-IP, SUMOylation/ubiquitination assays, SMURF1 competition experiments; validated in endometriosis and pancreatic cancer models\",\n      \"pmids\": [\"39672102\", \"41239468\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"SUMOylation site(s) on CTPS1 not mapped\", \"Whether these mechanisms operate in lymphocytes unknown\", \"Relative contribution of SMURF1 versus other E3 ligases not determined\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Demonstration that CTPS2 directly interacts with CTPS1 to dampen its activity and increase CTP sensitivity—independently of filament formation—and that H355A cytoophidium-null mutants support normal proliferation, separated CTPS1 catalytic function from its structural polymerization role.\",\n      \"evidence\": \"Interaction assays under non-polymerizing conditions, enzymatic activity with CTP inhibition curves, H355A mutagenesis with proliferation readouts\",\n      \"pmids\": [\"40957650\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of CTPS1–CTPS2 heterocomplexes in different tissues unknown\", \"Physiological contexts where cytoophidia confer a selective advantage remain undefined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the complete set of transcription factors driving CTPS1 induction upon immune activation, the precise SUMOylation sites and their regulation, the physiological function of cytoophidium assembly if it is dispensable for proliferation, and whether CTPS1-selective inhibitors can achieve therapeutic windows in clinical immunology and oncology settings.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No clinical trial data on CTPS1-selective inhibitors\", \"Role of cytoophidia in metabolic regulation versus sequestration unresolved\", \"Tissue-specific CTPS1/CTPS2 compensation map absent\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016874\", \"supporting_discovery_ids\": [0, 1, 4, 7]},\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [4, 7]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [2, 8, 11]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 1, 4, 7, 18]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 1, 3]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [6, 12, 13]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [6, 12]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 3, 6, 12, 13]}\n    ],\n    \"complexes\": [\n      \"CTPS1-CTPS2 heterocomplex\",\n      \"cytoophidium (CTPS1/IMPDH2 filament)\"\n    ],\n    \"partners\": [\n      \"CTPS2\",\n      \"IMPDH2\",\n      \"YBX1\",\n      \"HSPD1\",\n      \"RASD2\",\n      \"INHBA\",\n      \"SMURF1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}